

1 **Title:**

2 Cost of hypertension illness and associated factors among patients
3 attending hospitals in Southwest Shewa Zone, Oromia Regional State,
4 Ethiopia.

5 **Authors:**

6 Addisu Bogale ¹, Teferi Daba², Dawit Wolde Daka ²

7

8 ¹ Southwest Shewa zone health office, Woliso, Southwest Ethiopia.

9 ² Faculty of Public Health; Department of Health Economics, Management and Policy; Jimma
10 University, Jimma, Ethiopia.

11 Co-author contact details:

12 Addisu Bogale, E-mail: addisuub@gmail.com ; Teferi Daba, E-mail: tefedha@gmail.com

13 Corresponding author:

14 Full name: Dawit Wolde Daka

15 P.O.Box=378, Jimma University, Jimma, Ethiopia.

16 Tel. (+251)-966763913

17 E-mail: dave86520@gmail.com

18 **Abstract**

19 **Background:** Hypertension is a common vascular disease and the main risk factor for
20 cardiovascular diseases. The impact of hypertension is on the rise in Ethiopia, so that, it is
21 predictable that the cost of healthcare services will further increase in the future. We aimed to
22 estimate the total cost of hypertension illness among patients attending hospitals in Southwest
23 Shewa zone, Oromia Regional State, Ethiopia.

24 **Patients and methods:** Institution based cross-sectional study was conducted from July 1-30,
25 2018. All hypertensive patients who were on treatment and whose age was greater than eighteen
26 years old were eligible for this study. The total cost of hypertension illness was estimated by
27 summing up the direct and indirect costs. Bivariate and multivariate linear regression analysis was
28 conducted to identify factors associated with hypertension costs of illness.

29 **Results:** Overall, the mean monthly total cost of hypertension illness was US \$ 22.3 (95% CI,
30 21.3-23.3). Direct and indirect costs share 51% and 49% of the total cost, respectively. The mean
31 total direct cost of hypertension illness per patient per month was US \$11.39(95% CI, 10.6-12.1).
32 Out of these, drugs accounted of a higher cost (31%) followed by food (25%). The mean total
33 indirect cost per patient per month was US \$10.89(95% CI, 10.4-11.4). Educational status, distance
34 from hospital, the presence of companion and the stage of hypertension were predictors of the cost
35 of illness of hypertension.

36 **Conclusion:** The cost of hypertension illness was very high when compared with the mean
37 monthly income of the patients letting patients to catastrophic costs. Therefore, due attention
38 should be given by the government to protect patients from financial hardships.

39 **Key words:** Illness, total cost, direct cost, indirect cost, Region, Ethiopia.

40 **Introduction**

41 Hypertension is one of the main public health problem seen among adults worldwide.
42 Hypertension is often defined as Systolic Blood Pressure (SBP) ≥ 140 mmHg or Diastolic Blood
43 Pressure (DBP) ≥ 90 mmHg. It is the main risk factor to cardiovascular disease (CVD) such as
44 heart diseases and stroke (1,2).

45 Worldwide, 45% of deaths as the result of heart diseases and 51% of deaths due to stroke was
46 attributable to hypertension(3). In 2012 alone, 17.5 million people were died due to CVDs, which
47 translated to every three people deaths in ten (4). Out of these deaths, over half, 9.4 million, deaths
48 are caused by complications of hypertension(4,5). Hypertension was the fourth and seventh
49 contributor to premature deaths in developed and developing countries , respectively (6).

50 The prevalence of hypertension is in a high rise worldwide over time (7) and the prevalence varies
51 across the different regions and country income groups. Recent evidences indicated that an
52 estimated 1.13 billion people have hypertension worldwide. Out of these, the majority (around two
53 thirds) were located in low and middle income countries. The prevalence ranged from 27% in the
54 World Health Organization (WHO) Africa region to 18% in the WHO region of Americans. The
55 high rise in the prevalence of hypertension was attributed to the increase in the risk factors such as
56 physical inactivity, the consumption of tobacco and alcohol, unhealthy diet, overweight and obesity
57 in those population groups (2,7).

58 In Ethiopia evidences showed that the prevalence and impact of non-communicable diseases
59 (NCDs) including hypertension has increased over time(8). A meta analysis and other surveys
60 conducted in different parts of Ethiopia revealed that the prevalence of hypertesion was increasing
61 in Ethiopia. The prevalence was high and ranged from 24.4% to 34.7% (9–13). The latest WHO

62 published data in 2017 indicated that deaths attributed to hypertension reached 11,050 deaths or
63 1.74% of the total deaths in Ethiopia. The age adjusted death rate in Ethiopia was 25.14 per
64 100,000 of population and this ranked Ethiopia 38th in the world. Hypertension was ranked 11th
65 out of the top 20 causes of death in the country(14). Ethiopia was prone to double burden of
66 diseases, both infectious and non-infectious diseases, that requires a urgent government actions(15).

67 The government of Ethiopia (GoE) has expressed its commitment for tacking premature deaths
68 attributed to non-communicable diseases by signing the sustainable development goals
69 (SDGs)(16) and incorporating related targets within the national health sector transformation plan
70 (HSTP)(17). To effect this target, a comprehensive prevention and control strategic action plan of
71 NCDs including hypertension was developed at national level with a particular emphasis to
72 reducing risky behaviors(18).

73 Cost of health services is important determinant of the acceptability and utilization of health
74 services by the society. The goal of health system is improving the health conditions of citizens
75 through protecting financial catastrophes or hardships(19,20). The management of hypertension is
76 cost intensive and hence, it may cause economic burden on citizens(21–24). Society may not afford
77 available services leading to ineffectiveness of hypertension managements(25). Hypertension cost
78 of illness was determined by various factors such as the presence of co-morbidity, stage of illness
79 and distance to health facility(22,26). Therefore, it is crucial to quantify the cost of hypertension
80 illness and identify the factors that determines the cost of hypertension illness among patients in
81 Ethiopia.

82 Available investigations on the cost of hypertension illness in Ethiopia have focused on the direct
83 costs of illness (26) and to our best knowledge little was known about the indirect costs of
84 hypertension illness. Hence, the aim of this study was to estimate the cost of hypertension illness

85 among patients in four hospitals of Southwest Shewa zone, Oromia Regional State, Ethiopia. We
86 estimated the direct, indirect and total costs of hypertension illness. Moreover, we tried to identify
87 the potential predictors of the total costs of hypertension illness.

88 **Patients and methods**

89 **Study setting**

90 The study was conducted in four hospitals of Southwest Shewa zone from August 13 to September
91 2, 2018. Southwest Shewa zone is one among the zonal administrations located in Oromia
92 Regional State, 114 km far away from the capital city of Ethiopia, Addis Ababa. The total
93 population of the zone was 1,101,129. Southwest Shewa zone comprised of 3 government
94 hospitals, 1 other government organization (OGO) hospital, 54 health centers and 264 health posts.
95 The hospitals were named as St. Luke general hospital; Tulo Bolo, Ameya and Bantu primary
96 hospitals, respectively.

97 These hospitals provides high level curative services such as the management of non-
98 communicable diseases like hypertension, diabetes, coronary heart diseases and stroke to the
99 catchment population of the zone and neighboring zones.

100 **Study design and participants**

101 Institution based cross-sectional study design was employed and the perspective of patients was
102 used to estimate the cost of hypertension illness. All hypertensive patients who were on follow-
103 up at hospitals and whose age was greater than 18 years old and who have been taken
104 antihypertensive medications were eligible for this study. Pregnant women were excluded from
105 this study to avoid gestational hypertension, as its effect may not last long.

106 Study sample size was determined using a single population mean formula(27). A previous report
107 from Ethiopia public hospitals indicated that the mean or median drug prescription cost of
108 hypertension was 100 Ethiopian Birr (ETB) or US \$ 3.6 (SD 41.19 or 1.5)(26). By using the
109 assumptions above, the estimated sample size at 95% confidence interval and 4% absolute
110 allowable error (precision) yields 408 patients.

111
$$\text{Sample size (n)} = \frac{(Z_{1-\alpha/2})^2 \cdot (SD)^2}{(d)^2}$$

112 Where;

113 ✓ $Z_{1-\alpha/2}$ is the value obtained from the standard normal distribution table for 100 (1- α) %
114 confidence level and its value for 95% confidence level was 1.96.

115 ✓ SD= is the population standard deviation (41.19)(26)

116 ✓ d= is the absolute allowable error (or precision) in the estimation (4% of 100birr =4birr).
117 The allowable error in estimating the average cost of prescription of drug for hypertension
118 was 4 birr.

119 Though, as the number of hypertension patients on follow-up care (source population)) were less
120 than 10,000 in the study area (N=1451), we corrected the sample size to the actual population size
121 and this yields 318 patients. While, by adding 10% of non-response rate, the final estimated sample
122 size yields 354 patients.

123
$$\text{Sample size correction formula (nf)} = \frac{n_0}{1 + \frac{n_0}{N}}$$

124 The calculated sample size was proportionally allocated to each of the study hospitals based on
125 the caseload or hypertension patients per month. Accordingly, the number of patients per month

126 and sample size allocated for each hospitals were: St. Luke General hospital (N=620, n=152); Tulu
127 Bolo hospital (N=315, n=76); Amaya hospital (N=241, n=59); and Bantu hospital (N=275, n=67).
128 Each eligible patients who were presented to the study hospitals during the data collection period
129 were approached and interviewed.

130 Measurement

131 A structured data collection tools were used to gather data. The contents of the questionnaires were
132 developed based WHO protocol for survey to determine costs of TB treatment program (28)and
133 other related literatures(26).

134 The contents of the questionnaires were translated to local language (Afan Oromo) by an
135 experienced translator and back translated to English with an independent translator for
136 consistency. Five data collectors with a qualification of diploma nurse and who had also received
137 additional training on the data collection questionnaires and research ethics were participated on
138 data collection. The overall data collection processes were closely monitored and supervised by
139 two health professionals who had a qualification of bachelor's degree. Each eligible patients who
140 visits the hospitals were approached and interviewed after explaining the aim of the study and
141 obtaining a consent for participation.

142 Techniques of cost estimation

143 The cost of hypertension illnesses analysis was conducted from the perspective of patients and a
144 prevalence based model was employed to estimate cost(29). The main outcome variable was total
145 cost of hypertension illness and it referred to the cost paid by patients as a consequence of a
146 hypertension illness, typically it included both the direct and the indirect costs associated with

147 hypertension illness. That means, total cost equals to the sum of direct and indirect cost of
148 hypertension illness.

149 Direct cost referred to the opportunity cost of resources used for treating hypertension patients
150 such as direct medical cost and direct non-medical cost. Direct medical cost was the amount of
151 money that was paid for registration, laboratory investigation and medication or drugs in the study
152 health facilities during the data collection period as presented below:

- 153 ➤ Cost of hospital admission=Number of days admitted multiplied by cost per day
- 154 ➤ Investigation cost=Number of investigations carried out multiplied by cost of each
155 investigations (unit price)
- 156 ➤ Cost of drug=Number of prescription given multiplied by cost of each drugs (unit price)

157 Direct non-medical costs referred to the amount of money that was paid for transportation, food,
158 and accommodation for both patients and their caregiver (companion) to visit the hospital.
159 Transportation costs were estimated based on the number of visits made to hospitals (round trips)
160 to seek care and logging or accommodation costs were estimated based on the number of days of
161 stay at hospitals as described below:

- 162 ➤ Cost of transportation=Number of round trips from home to care provider multiplied by
163 the cost of single trip
- 164 ➤ Cost of lodging or accommodation=Money spent for food and accommodations multiplied
165 by number of days patients and their companion were away from their home

166 Indirect cost was the value of resources lost due to a particular illness. Indirect costs were
167 associated with loss of working time of the hypertension patients and their caregivers (companion).
168 The loss of income of a person was due to absenteeism or missing a business appointment. Loss
169 of income or earning was calculated for both employed and unemployed patients as shown below:

170 ➤ Loss of earning for employed = $\frac{\text{Previous monthly income} * \text{length of stay}}{\text{No of day in the month}}$

171 ➤ Loss of earning for unemployed = $\frac{\text{Previous daily wage rate}(\text{minimum wage}) * \text{length of stay}}{\text{No of working day in the month}}$

172 The costs of illnesses (both direct and indirect) were estimated as expressed for a 30-day period.

173 The valuation of direct and indirect costs were based on a record review and patients recall.

174 The direct costs of hypertension illness were estimated by using micro-costing and bottom-up
175 approaches(29). Accordingly, the healthcare consumptions were collected at individual patient
176 level and the illness costs were also modeled at the same level. The direct costs such as costs of
177 drugs, laboratory investigations and registrations were estimated based on the amount consumed
178 by each patients. Health care consumption data were obtained through review of hospitals
179 outpatient department (OPD) registration books and follow-up cards.

180 The indirect costs were estimated in terms of the productivity time losses of patients and their
181 caregivers (companion). The human capital approach was used to value the productivity time
182 losses(29). Indirect costs were estimated for patients' time lost from work during travel and
183 consultation at care providers. First, the time forgone in seeking care and the productivity time lost
184 were estimated. Then, the time forgone in seeking care and the productivity time lost were
185 converted in to the daily indirect costs based on the daily wage rate. Finally, the value obtained by
186 doing so was multiplied by the number of working days lost.

187 For monthly paid patients and companion, the daily wage rate was estimated by dividing their net
188 monthly salary by 30 days. The income loses to patients who had no permanent job and farmers
189 were estimated using local daily wage rate (Ethiopian birr per day) for unskilled labor and number
190 of working days per month. The local daily wage rate for unskilled labor were obtained from the
191 response of patients.

192 Whereas, the daily wage rate of daily paid patients and companion were estimated based on the
193 patients reported daily earnings. The indirect costs of unemployed patients, such as students and
194 patients who were not working due to physical or mental disability, were not considered in the
195 calculations.

196 All direct costs, indirect costs and productivity losses were initially collected in Ethiopian currency
197 (birr) and then converted to US \$ during the analysis. A currency exchange rate of 1US \$=27.471
198 Ethiopian Birr as of August 2018 was employed in the analysis.

199 Data sources

200 The sources of information's for estimating the costs of hypertension illness were both patients
201 and medical records. Direct cost of illness was estimated based on the information obtained
202 through patient interview and record review. Information related to indirect costs such as costs of
203 transportation and logging were gathered through patients and companion interviews (Table 1).

204 Data analysis

205 Paper based data were checked for completeness and consistency. Following this, data were
206 entered by using Epidata version 3.1 and exported to SPSS 20 for analysis.

207 The analysis was performed in such a way that, first, descriptive statistics was conducted to analyze
208 information related to the characteristics of patients and to estimate the costs of hypertension
209 illness. Following this, cost of illness data were checked for normality by using plots (Q-Q plots
210 and histograms) and Kolmogorov-Smirnov test for normality ($P>0.05$). By doing so, the cost data
211 were found to be right skewed and log transformation was performed to approximately conform
212 the skewed data to normality.

213 Multivariate linear regression analysis was conducted to identify the predictors of the total cost of
214 hypertension illness among patients.

215 In the regression model, independent variables with a probability value (P-value < 0.05) have been
216 entered and only statistically significant variables (P-value < 0.05) were included into the final
217 model and interpreted.

218 Ethical Considerations

219 Research protocol was submitted to Jimma University Institute of health ethics review board and
220 ethical clearance was obtained (protocol number IHRPGD/453/2018, July 2018). Research ethical
221 clearance and permission was also obtained from Oromia regional health bureau and Southwest
222 Shewa zone health department. The objective of the study was briefly explained to research
223 participants followed by consent as assurance to their voluntary participation. The confidentiality
224 of patient's information was maintained throughout the data collection and analysis processes.
225 Codes were used instead of patient identifying information's and patient's data were kept in a
226 locked cabinet and in a password secured computers. Except the research team members, no one
227 can access the patients data without due consent of individual patients.

228 Results

229 Participation

230 Out of the total planned 354 patients, 349 were participated in the study making a response rate of
231 98.6%.

232 Characteristics of patients

233 Table 2 presented the characteristics of patients in the study area. The mean age of patients was 52
234 years (SD 14). The youngest patient was 22 years and the oldest one was 88 years. A bit more than
235 half (52%) of patients were male. The majority of patients were married (80%), orthodox religion
236 followers (56%), have no education (44%), employed (78%) and from urban settings (60%) (Table
237 2). The average monthly income of patients and households were 115.4 US \$ (SD 70.1) and 136.8
238 US \$ (SD 105.9), respectively.

239 Cost of hypertension illness

240 Cost by patients

241 Table 3 presented the direct and indirect cost of hypertension illness among patients on follow-up
242 care by cost category. The estimated total direct cost of hypertension illness was 3032.3 US \$.The
243 mean direct cost of hypertension illness was US \$ 8.8 (95% CI, 8.2-9.3). Most (60%) of the direct
244 costs of hypertension illness were attributed to medical costs (mean annual cost, US \$ 5.2; 95%
245 CI, 4.8-5.5). The direct medical costs comprised of cost for drugs, laboratory tests, registration and
246 cost for non-prescribed drugs. Slightly over two-thirds (69%) of total medical costs were
247 contributed by the cost of drugs alone (mean annual cost, US \$ 3.6; 95% CI, 3.4-3.8). While costs
248 for laboratory tests and registration were accounted of 13% (mean annual cost, US \$ 1.2; 95% CI,
249 1.1-1.4) and 7% (mean annual cost, US \$ 0.4; 95% CI, 0.37-0.39) of the total medical costs,
250 respectively (Table 3).

251 On average patients have visited hospitals once per month and half of patients have used bus as a
252 means of transportation to visit hospitals. The mean lost earning day of patients due to hypertension

253 illness was one working day. The total cost of lost earning was US \$ 1, 927.9 and on average each
254 patients paid US \$ 6.7 (95% CI, 6.3-7.0) (Table 3).

255 Cost by companions

256 Table 4 presented the costs of hypertension illness paid by companions. Out of the total patients
257 who have visited hospitals (349), the majority (87%; 95% CI, 83-90) had family or friend that
258 accompany them. Half of the companions (52%; 95%, CI 46-57) have lost some portion of their
259 income as they care patients. The mean direct cost of companion was US\$ 3.1 (95% CI, 2.7-3.6)
260 and the mean forgone earning by the companion as the result of hypertension illness was US \$ 6.2
261 (95% CI, 5.9-6.5) (Table 4).

262 Total cost of hypertension illness

263 Table 5 presented the total cost of hypertension illness. The total cost of hypertension illness was
264 US \$ 7,773.5(mean monthly cost, US \$ 22.3; 95% CI, 21.3-23.3). Out of these, direct costs
265 accounted of 51% or US \$ 3,973.8. The mean monthly and annual direct cost of hypertension
266 illness per patient were US\$ 11.4 (95% CI, 10.6-12.1) and US \$ 136.6 (95% CI, 127.7-145.5),
267 respectively (Table 5).

268 The mean monthly and annual indirect costs of hypertension illness per patient were US \$ 10.9
269 (95% CI, 10.4-11.4) and US \$ 130.7, respectively. Indirect cost was the time devoted by
270 hypertension patients and companion in one month recall period. It included detail time spent by
271 patients and companion. Indirect cost was expressed by the lost days of patients and companion
272 during the follow-up visits or seeking treatments. A total of 833 days were used by patients and
273 companion with median of 1.9 days in one month period. The time spent by patients and
274 companion to visit hospital was 26,585 minute with median of 60 minutes (round trip) (Table 5).

275 Predictors of cost of hypertension illness

276 Table 6 presented the bivariate and multivariate linear regression analysis results. In the bivariate
277 linear regression analysis variables such as gender, marital status, educational status, family size,
278 residence, distance from hospital, presence of companion and stage of hypertension were
279 associated with total cost of hypertension illness.

280 After adjusted for other independent variables, educational status, distance from hospital, presence
281 of companion and stage of hypertension were statistically associated with the total cost of illness.
282 Twenty three percent (23%) of the variability in the total cost of hypertension illness was explained
283 by these variables (Table 6).

284 Patients with no education have a higher total cost of hypertension illness compared to patients
285 with a primary educational level (β -coefficient=-0.07; 95% CI, (-0.124,-0.020).

286 The total cost of hypertension illness increased with the increase in distance to hospital. With a
287 unit increase in distance to hospitals, the total cost of hypertension illness increased by about US
288 \$ 0.003(95% CI, 0.002, 0.004) keeping the other variables constant.

289 Moreover, the total cost of hypertension illness was associated with the presence of companion
290 and the stage of hypertension. The total cost of hypertension was higher among patients who have
291 companion compared to those who didn't have (β -coefficient=0.096; 95% CI, 0.057, 0.135).

292 Likewise, the total cost of hypertension illness was higher among patients in the hypertension stage
293 of two compared to patients in the prehypertension stage (β -coefficient=0.070; 95% CI, 0.023,
294 0.118) (Table 6).

295 **Discussion**

296 Cost of illnesses analysis is useful to understand the burden of a particular disease in a society(29–
297 31). In this study we estimated the cost of hypertension illness among patients on follow-up care.
298 The estimated total cost of hypertension illness was 7775.5 USD and out of these direct cost
299 accounted of 51%. The average annual cost of hypertension illness among patients was US \$ 267.2.
300 Likewise, the annual mean direct and indirect costs per patients were US \$ 136.6 and US \$ 130.7,
301 respectively. In this study variables such as educational status, distance from hospital, the presence
302 of companion and stage of hypertension were the predictors of the total cost of hypertension illness
303 in the study area.

304 The cost of hypertension illness was lower that a study conducted in Kenya, where the mean annual
305 direct and indirect cost to patient were US\$ 304.8 (95% CI, 235.7-374.0) and US\$ 171.7 (95% CI,
306 152.8-190.5), respectively (23). However, the cost of hypertension illness was higher than a study
307 conducted in India (32) and Addis Ababa (26). This difference might be due to variation in
308 settings, period and methods of cost estimation employed.

309 A bit over half of the total cost of hypertension illness was contributed by direct medical and direct
310 non-medical costs. Most of the direct costs were due to drugs followed by accommodation and
311 transportation. In the study setting, direct medical cost accounted of 29% of the direct cost of
312 hypertension illness. A comparable result was also reported in other settings in which much of the
313 cost of hypertension illness was attributed to medicines(21–23,26,32,33). This might be related to
314 the high cost of hypertension drugs and this implied a higher rates of catastrophic costs on
315 hypertension patients.

316 Nonetheless, the indirect costs of hypertension illness were also equally important. These costs
317 included the time spent by patients and their companion, and expressed as lost work days. The
318 majority of patients had companion and the mean forgone earning by the companion due to
319 hypertension illness was US\$ 6.2. The estimated average annual indirect cost of hypertensive
320 illness was US \$ 130.7 and this is lower than a report from Kenya(23). However, the indirect cost
321 of hypertensive illness was high in the study area and it accounted of 49% of the total cost of
322 illness. Indirect cost of hypertensive illness was attributed to the travel time to the hospital and
323 absent from work. This indicates the need for expanding hypertension management centers and
324 enhancing the control of hypertension in a community. In Ethiopia the coverage of non-
325 communicable diseases management services was low and increasing steadily (34).

326 The cost of hypertension illness was determined by educational status, distance from the hospital,
327 presence of companion and the stage of hypertension illness. The cost of hypertension illness was
328 higher in no educated patients than the primary level education patients. This might be due to the
329 reason that in the study setting most of the patients with a no educational status were at stage two
330 of hypertension and the complications related to hypertension may let them to cost more. The total
331 cost of hypertension was also associated with the presence of companion and distance to hospital.
332 With a unit increase in distance to hospital, the cost of hypertension illness increased by about
333 0.003 US \$. This is due to the fact that the companion consumption (food and transport) and the
334 transportation cost of patients to visit hospitals may increases the total cost of hypertension illness.
335 Likewise, patients who were in stage two of hypertension have a higher cost of illness than those
336 in the prehypertension stage. This implies that the complications of hypertension is a significant
337 contributor to increase in the cost of illness and this warrants the early diagnosis and management
338 of hypertension. Our findings are comparable to other reports elsewhere(21,32).

339 Though our study have a many strengths, it has also some limitations. The cost of illness analysis
340 was limited to patient's perspective and doesn't addressed other costs of the health system (such
341 as costs related to the provider, family and society at large). Moreover, the intangible cost (costs
342 of pain, suffering, stigma and discrimination) associated with hypertensive illness were not also
343 addressed in our study.

344 **Conclusion**

345 Overall, this study have revealed that the total cost of hypertension illness was high in the study
346 area. The mean total cost of hypertension illness was high compared to the mean monthly income
347 of patients and households, letting patients to catastrophic costs. Unless urgent measures were
348 taken, the increased prevalence of hypertension combined to the high cost of hypertension
349 management in Ethiopia may bare individuals to financial hardships. Thus, the government should
350 take attention in preventing further catastrophic costs resulted from the complications and
351 mortality of hypertension.

352 **Acknowledgments**

353 Our sincere gratitude should goes to the participants of the study and the administrative offices for
354 their cooperation throughout the data collection process.

355 **Author contributions**

356 All authors contributed toward conceiving idea, study design and data analysis. DWD drafted the
357 manuscript and AB and TB revised the paper. All authors also gave final approval of the paper.

358 **Disclosure**

359 All authors declared no conflict of interest.

360 **References**

- 361 1. American College of Cardiology. Guideline for the Prevention , Detection , Evaluation ,
362 and Management of High Blood Pressure in Adults [Internet]. 2017. Report No.: 23976.
363 Available from: [https://www.acc.org/~media/Non-Clinical/Files-PDFs-Excel-MS-Word-](https://www.acc.org/~media/Non-Clinical/Files-PDFs-Excel-MS-Word-etc/Guidelines/2017/Guidelines_Made_Simple_2017_HBP.pdf)
364 [etc/Guidelines/2017/Guidelines_Made_Simple_2017_HBP.pdf](https://www.acc.org/~media/Non-Clinical/Files-PDFs-Excel-MS-Word-etc/Guidelines/2017/Guidelines_Made_Simple_2017_HBP.pdf)
- 365 2. World Health Organization. Hypertension: Key facts [Internet]. 2019. Available from:
366 <https://www.who.int/news-room/fact-sheets/detail/hypertension>
- 367 3. World Health Organization. A global brief on hypertension: Silent killer, global public
368 health crisis. World Health Day 2013 [Internet]. 2013. Available from: [https://ish-](https://ish-world.com/downloads/pdf/global_brief_hypertension.pdf)
369 [world.com/downloads/pdf/global_brief_hypertension.pdf](https://ish-world.com/downloads/pdf/global_brief_hypertension.pdf)
- 370 4. Campbell N, Lackland D, Niebylski M. High Blood Pressure : Why Prevention and
371 Control are Urgent and Important . A 2014 Fact Sheet from the World Hypertension
372 League and the International Society of Hypertension Increased blood pressure is the
373 leading risk factor for death and for disability. *Int Soc Hypertens.* 2014;(1):5.
- 374 5. The P, On P, Killer THES. HYPERTENSION :PUTTING THE PRESSURE ON THE
375 SILENT KILLER. *IFPMA*; 2016. 3–19 p.
- 376 6. Lloyd-Jones DM, Levy D. Epidemiology of Hypertension. *Hypertens A Companion to*
377 *Braunwald’s Hear Dis.* 2013;61(February):1–22.
- 378 7. Salem H, Hasan DM, Eameash A, El-Mageed HA, Hasan S, Ali R. Worldwide Prevalence

- 379 of Hypertension: a Pooled Meta-Analysis of 1670 Studies in 71 Countries With 29.5
380 Million Participants. *J Am Coll Cardiol* [Internet]. 2018;71(11):A1819. Available from:
381 [http://dx.doi.org/10.1016/S0735-1097\(18\)32360-X](http://dx.doi.org/10.1016/S0735-1097(18)32360-X)
- 382 8. Misganaw Dr. A, Mariam DH, Ali A, Araya T. Epidemiology of major non-
383 communicable diseases in Ethiopia: A systematic review. *J Heal Popul Nutr* [Internet].
384 2014;32(1):1–13. Available from: <http://www.bioline.org.br/pdf?hn14001>
- 385 9. Roba HS, Beyene AS, Mengesha MM, Ayele BH. Prevalence of Hypertension and
386 Associated Factors in Dire Dawa City, Eastern Ethiopia: A Community-Based Cross-
387 Sectional Study. *Int J Hypertens*. 2019;
- 388 10. Belachew A, Tewabe T, Miskir Y, Melese E, Wubet E, Alemu S, et al. Prevalence and
389 associated factors of hypertension among adult patients in Felege-Hiwot Comprehensive
390 Referral Hospitals, northwest, Ethiopia: A cross-sectional study. *BMC Res Notes*
391 [Internet]. 2018;11(1):876. Available from: <https://doi.org/10.1186/s13104-018-3986-1>
- 392 11. Abebe S, Yallem WW. Prevalence of hypertension among adult outpatient clients in
393 hospitals and its associated factors In Addis Ababa , Ethiopia : a hospital based cross -
394 sectional study. *BMC Res Notes* [Internet]. 2019;12:87. Available from:
395 <https://doi.org/10.1186/s13104-019-4127-1>
- 396 12. Abebe SM, Berhane Y, Worku A, Getachew A. Prevalence and associated factors of
397 hypertension: A crossectional community based study in Northwest Ethiopia. *PLoS One*.
398 2015;10(4):1–11.
- 399 13. Kibret KT, Mesfin YM. Prevalence of hypertension in Ethiopia: A systematic meta-
400 analysis. *Public Health Rev* [Internet]. 2015;36(1):14. Available from:

- 401 <http://dx.doi.org/10.1186/s40985-015-0014-z>
- 402 14. World Health Organization. Age Adjusted Death Rate Estimate. The Health Profile of
403 Ethiopia. 2017. Accessed at: [https://www.worldlifeexpectancy.com/country-health-](https://www.worldlifeexpectancy.com/country-health-profile/ethiopia)
404 [profile/ethiopia](https://www.worldlifeexpectancy.com/country-health-profile/ethiopia).
- 405 15. Misganaw A, Haregu TN, Deribe K, Tessema GA, Deribew A. National mortality burden
406 due to communicable , non-communicable , and other diseases in Ethiopia , 1990 – 2015 :
407 findings from the Global Burden of Disease Study 2015. *Popul Health Metr* [Internet].
408 2017;15:29. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5521057/>
- 409 16. Federal Democratic Republic of Ethiopia National Plan Commission. The 2017 Voluntary
410 National Reviews on SDGs of Ethiopia: Government Commitments, National Ownership
411 and Performance Trends. Addis Ababa [Internet]. 2017. Available from:
412 <https://sustainabledevelopment.un.org/content/documents/16437Ethiopia.pdf>
- 413 17. FMOH of Ethiopia. Health Sector Transformation Plan (HSTP) 2015/16-2019/20
414 [Internet]. 2015. Available from: [https://www.globalfinancingfacility.org/ethiopia-health-](https://www.globalfinancingfacility.org/ethiopia-health-sector-transformation-plan-201516-201920)
415 [sector-transformation-plan-201516-201920](https://www.globalfinancingfacility.org/ethiopia-health-sector-transformation-plan-201516-201920)
- 416 18. FDRE MOH. National Strategic Action Plan (NSAP) for Prevanetion and Control of Non-
417 communicable diseases in Ethiopia. 2014-2016 [Internet]. 2016. Available from:
418 [https://www.iccp-portal.org/system/files/plans/ETH_B3_National Strategic Action Plan](https://www.iccp-portal.org/system/files/plans/ETH_B3_National%20Strategic%20Action%20Plan%20for%20Prevention%20and%20Control%20of%20Non-Communicable%20Diseases%20-%20Final.pdf)
419 [%28NSAP%29 for Prevention and Control of Non-Communicable Diseases - Final.pdf](https://www.iccp-portal.org/system/files/plans/ETH_B3_National Strategic Action Plan %28NSAP%29 for Prevention and Control of Non-Communicable Diseases - Final.pdf)
- 420 19. GAVI CSO Project fact sheet. What are the Health System Building Blocks ? [Internet].
421 2013. Available from:
422 https://hssfactsheets.weebly.com/uploads/4/8/1/1/48110245/gavi_cso_fact_sheet_no_5_bu

- 423 ilding_blocks.pdf
- 424 20. Christopher Murray and Julio Frenk. A WHO Framework for Health System Performance
425 Assessment. Evidence and Information for policy. World Health Organization [Internet].
426 Available from:
427 [https://www.researchgate.net/publication/12402824_A_WHO_Framework_for_Health_Sy](https://www.researchgate.net/publication/12402824_A_WHO_Framework_for_Health_System_Performance_Assessment)
428 stem_Performance_Assessment
- 429 21. Nguyen T, Bach T, Nguyen Y, Nguyen TT, Hac VV, Le HH. Direct costs of hypertensive
430 patients admitted to hospital in Vietnam – a bottom-up micro-costing analysis. BMC
431 Health Serv Res. 2014;14:514.
- 432 22. Alefán Q, Ibrahim MIM, Razak TA, Ayub A. COST OF TREATING HYPERTENSION
433 IN MALAYSIA. Asian J Pharm Clin Res. 2009;2(1):1–5.
- 434 23. Njoroge M, Nguhiu P, Oyando R, Kirui F, Mbui J, Sigilai A, et al. Patient costs of
435 hypertension care in public health care facilities in Kenya. Int J Heal Plann Mgmt.
436 2019;34:e1166–e1178.
- 437 24. Wagner AK, Valera M, Graves AJ, Laviña S, Ross-degnan D. Costs of hospital care for
438 hypertension in an insured population without an outpatient medicines benefit : an
439 observational study in the Philippines. BMC Health Serv Res. 2008;8:161.
- 440 25. Baker-goering MM, Roy K, Howard DH. Relationship Between Adherence to
441 Antihypertensive Medication Regimen and Out- of-Pocket Costs Among People Aged 35
442 to 64 With Employer-Sponsored Health Insurance. PUBLIC Heal Res Pract POLICY.
443 2019;16:180381.

- 444 26. Bedane SN. Out of Pocket Expenditures among Hypertensive Patients and their
445 Households who Visit Public Hospitals in Addis Ababa , Ethiopia , 2016. Heal Econ
446 Outcome Res Open Access. 2018;4(1):1–7.
- 447 27. Dhar M, Binu V, Mayya S. Some basic aspects of statistical methods and sample size
448 determination in health science research. AYU (An Int Q J Res Ayurveda) [Internet].
449 2014;35(2):119–23. Available from:
450 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279315/>
- 451 28. World Health Organization Global TB Programme. Protocol for survey to determine
452 direct and indirect costs due to TB and to estimate proportion of TB-affected households
453 experiencing catastrophic costs due to TB. November [Internet]. 2015. Available from:
454 [http://www.who.int/tb/advisory_bodies/impact_measurement_taskforce/meetings/tf6_bac
455 kground_5a_patient_cost_surveys_protocol.pdf?ua=1](http://www.who.int/tb/advisory_bodies/impact_measurement_taskforce/meetings/tf6_background_5a_patient_cost_surveys_protocol.pdf?ua=1)
- 456 29. Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol [Internet].
457 2014;20:327–37. Available from:
458 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278062/>
- 459 30. Segel JE. Cost-of-Illness Studies — A Primer. RTI International. RTI-UNC Center of
460 Excellence in Health Promotion Economics [Internet]. 2006. p. 1–39. Available from:
461 <https://pdfs.semanticscholar.org/3bbf/0a03079715556ad816a25ae9bf232b45f2e6.pdf>
- 462 31. Byford S, Torgerson DJ, Raftery J. Cost of illness studies. BmJ [Internet]. 2000;320:1335.
463 Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1127320/>
- 464 32. Sitanshu Sekhar Kar, Vinoth Kumar Kalidoss, Uma Vasudevan SG. Cost of care for
465 hypertension in a selected health center of urban Puducherry : An exploratory cost-of-

466 illness study. Int J Non-communicable diseases [Internet]. 2018;3(3):98–103. Available
467 from: [http://www.ijncd.org/article.asp?issn=2468-](http://www.ijncd.org/article.asp?issn=2468-8827;year=2018;volume=3;issue=3;spage=98;epage=103;aulast=Kar)
468 [8827;year=2018;volume=3;issue=3;spage=98;epage=103;aulast=Kar](http://www.ijncd.org/article.asp?issn=2468-8827;year=2018;volume=3;issue=3;spage=98;epage=103;aulast=Kar)

469 33. Donglan Zhang, Guijing Wang, Ping Zhang, Jing Fang, and Carma Ayala R. Medical
470 Expenditures Associated With Hypertension in the U.S., 2000–2013. Am J Prev Med.
471 2017;53(6):S164–S171.

472 34. Ethiopian Public Health Institute. Services Availability and Readiness Assessment (
473 SARA). 2018.

474

475

476

477

478

479

480

481

482

483

484 Table 1: Cost item, data source and data type for cost of hypertension illness estimation among
485 patients in South West Shewa Zone hospitals, Oromia Regional State, Ethiopia. August 2018

Cost category	Data source	Method of data collection	Data type
Direct Medical Cost	Patient/health facility	Patient interview/record review	Cost of registration, drugs, laboratory, Admin cost ,if any investigations
Direct non-Medical Costs	Patient	Patient interview	Cost of transport for patients/Escort, lodging accommodation
Indirect Medical Cost	Patient	Patient interview	Income loss by patients and their families/relatives

486

487

488

489

490

491

492

493

494

495 Table 2. Characteristics of hypertensive patients at hospitals of Southwest Shewa zone, Oromia
496 regional state, Ethiopia. August 2018

Variables	Observations	Mean/proportion (95% CI)
	(n=349)	
Age (mean± SD)	51.2 (±13.9)	51.2 (50-53)
Gender		
Male	181	52% (47-57%)
Female	168	48% (43-53%)
Total		
Marital status		
Married	281	80% (76-84%)
Never married/single	27	8% (5-11%)
Widowed/ Divorced	41	12% (9-16%)
Religion		
Orthodox	202	58% (53-63%)
Muslim	78	22% (18-27%)
Protestant	69	20% (16-24%)
Highest education level		
No education	154	44% (39-49%)
Primary	57	16% (13-21%)
Secondary	68	20% (16-24%)
Higher	70	20% (16-25%)
Employment status		

Formal employment	144	41% (36-47%)
Informal/unemployed	205	59% (54-64%)
Family size		
1-3	49	14% (11-18%)
4-6	203	58% (53-63%)
>6	97	28% (23-33%)
Residence		
Urban	210	60% (55-65%)
Rural	139	40% (35-45%)
Average distance from hospital in (km)		
<10	169	48% (43-54%)
11-20	57	16% (13-21%)
21-30	42	12% (9-16%)
31-40	36	11% (7-14%)
41-50	20	6% (4-9%)
50+	25	7% (5-10%)
Illness duration		
1-5 y	242	69% (64-74%)
>5 y	107	31% (26-36%)
Stage of hypertension		
Prehypertension	113	32% (28-37%)
Stage I	161	46% (41-51%)
Stage II	75	22% (17-26%)

497 Table 3: Patient direct and indirect costs of hypertension illness at hospitals of Southwest Shewa
 498 zone, Oromia region, Ethiopia. August 2018 (US \$)

Cost item	Observations	Sum	Mean ± SD (Median)	95% CI for mean
Total Direct Cost	349	3,032.252	8.8±4.9(7.6)	(8.2-9.3)
Direct medical cost	349	1,804.230	5.2±3.3(4.7)	(4.8-5.5)
Cost of prescribed drugs	349	1,247.752	3.6±1.9(3.3)	(3.4-3.8)
Cost of different laboratory tests	186	231.371	1.2±0.9(0.9)	(1.1-1.4)
Cost registrations	349	133.413	0.38±0.1(0.4)	(0.37-0.39)
Cost of non-prescribed drugs	52	191.693	3.7±4.4(2.6)	(2.5-4.9)
Direct non-medical cost	339	1,228.022	3.6±3.2(2.9)	(3.3-3.9)
Cost of food during visit	278	505.078	1.8±1.5(1.5)	(1.6-1.9)
Cost of transport	302	369.335	1.2±1.2(0.7)	(1.1-1.4)
Cost of sport (gym) per month	87	353.609	4.1±4.2(3.6)	(2.8-4.5)
Income lost by patients	290	1,927.89	6.7±3.4	(6.3-7.0)
Number of outpatient visit(in number)	349	396	1.0±1.0	(0.9-1.1)
Days absent from work	349	459	1.3±1.3	(1.2-1.5)
Travel time to the hospital (in minute)	349	14,145	40.5±34.5	(36.9-44.1)
Waiting time in the hospital (in minutes)	349	10,715	30.7±14.7	(29.2-32.2)

499 Abbreviations: US \$, United States dollar; SD, standard deviation; CI, confidence interval

500

501 **Table 4:** Companion direct and indirect costs of hypertension illness at hospitals of South West
 502 Shewa Zone, Oromia Regional State, Ethiopia. August 2018 (US \$)

Cost category	Observations	Sum	Mean ± SD (Median)	95% CI for mean
Direct cost by companions	302	941.5	3.1±4(2.2)	(2.7-3.6)
Payment for Food	247	493.2	1.9±3.8(1.1)	(1.5-2.5)
Transportation Fee	302	369.3	1.2±1.2(0.7)	(1.1-1.4)
Cost for Other expenses	33	78.9	2.4±1.9(2.4)	(1.7-3.1)
Indirect cost by companions (income lost by companions)	302	1,871.8	6.2±2.3(5.5)	(5.9-6.5)
Travel time by caregivers in minute/month	302	12,440	41.2±34.9(30.0)	(37.3-45.1)
Days absent from work to accompany/month	302	376	1.0±1.0(1.0)	(0.9-1.1)

503 Abbreviations: US \$, United States dollar; SD, standard deviation; CI, confidence interval

504

505

506

507

508 **Table 5:** Total cost of hypertension illness at hospitals of Southwest shewa zone, Oromia regional
 509 state, Ethiopia. August 2018 (US \$)

Cost category	Observations	Sum	Mean \pm SD (Median)	95% CI for mean
Total cost of hypertension	349	7,773.47	22.3\pm9.4(20.8)	(21.3-23.3)
Total direct cost of patients and companions	349	3,973.75	11.4\pm7.1(10.0)	(10.6-12.1)
Direct medical costs	349	1,804.23	5.2\pm3.4(4.7)	(4.8-5.5)
Cost of prescribed drug	349	1,247.752	3.6 \pm 1.9(3.3)	(3.4-3.8)
Cost of laboratory test	186	231.371	1.2 \pm 0.9(0.9)	(1.1-1.4)
Cost of registration card	349	133.413	0.4 \pm 0.1(0.4)	(0.37-0.39)
Cost non-prescribed drug	52	191.693	3.7 \pm 4.4(2.6)	(2.5-4.9)
Direct non-medical costs	339	2,169.52	6.5\pm5.9(5.2)	(5.9-7.1)
Cost of Food	299	998.25	3.3 \pm 4.2(2.2)	(2.9-3.8)
Cost of transport	302	738.67	2.5 \pm 2.3(1.6)	(2.2-2.7)
Cost for sport(gym)	87	353.61	4.2 \pm 4.2(3.6)	(3.3-5.0)
Other costs	33	78.99	2.4 \pm 1.9(2.4)	(1.7-3.1)
Indirect costs of patients and companions				
Income lost by patients & companions	349	3,799.72	10.9\pm5.0(10.9)	(10.4-11.4)
Travel time to the hospital in minute/month	349	26,585.00	76.3 \pm 67.9(60.0)	(69.1-83.4)
Absent from works in days/month	349	833.00	2.0 \pm 1.0(1.9)	(1.9-2.1)

510 Abbreviations: US \$, United States dollar; SD, standard deviation; CI, confidence interval

511

512 Table 6: Predictors of the total cost of hypertension illness among patients at hospitals of
 513 Southwest Shewa zone, Oromia regional state, Ethiopia. August 2018(US \$)

Variables	Observations	Unadjusted β coefficient (95% CI)	Adjusted β coefficient (95% CI)
Age in years (Mean \pm SD)	51.2 (\pm 13.9)	0.0001(-0.001,0.002)	
Gender			
Male	181		
Female	168	-0.070(-0.113, -0.027)*	-0.037(-0.077,-0.004)
Educational status			
No education	154		
Primary	57	-0.068(-0.126,-0.009)*	-0.072(-0.124,-0.020)*
Secondary	68	0.007(-0.047,0.062)	
Tertiary	70	0.002(-0.052,0.056)	
Marital status			
Married	281		
Single	27	0.030(-0.051,0.112)	
Divorced/widowed	41	-0.091(-0.157,-0.024)*	-0.057(-0.121,0.006)
Family size			
1-3	49		
4-6	203	0.106(0.044,0.169)*	0.029(-0.010,0.068)
>6	97	0.122(0.050,0.195)	
Residence			
Urban	210		
Rural	139	0.062(0.018,0.106)*	0.020(-0.021,0.060)
Distance from hospital (Km)	21.6 \pm 23.7	0.003(0.002,0.004)*	0.003(0.002,0.004)*
Presence of companion			
Yes	153	0.106(0.064-0.149)*	0.096(0.057,0.135)*
No	196		
Stage of hypertension			
Pre-hypertension	113		

Stage one	161	-0.007(-0.051,0.036)	
Stage two	75	0.074(0.021,0.126)*	0.070(0.023,0.118)*
Duration of hypertension illness			
1-5 year	242		
>5 year	107	-0.027(-0.074,0.020)	
Presence of comorbidity			
Yes	227		
No	122	0.012(-0.034,0.057)	

514 Abbreviations: US \$, United States dollar; SD, standard deviation; CI, confidence interval;

515 *P-value<0.05

516